{ "instance": { "irwd-20220331x10q.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 196, "dts": { "calculationLink": { "local": [ "irwd-20220331_cal.xml" ] }, "definitionLink": { "local": [ "irwd-20220331_def.xml" ] }, "inline": { "local": [ "irwd-20220331x10q.htm" ] }, "labelLink": { "local": [ "irwd-20220331_lab.xml" ] }, "presentationLink": { "local": [ "irwd-20220331_pre.xml" ] }, "schema": { "local": [ "irwd-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 502, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 21, "http://xbrl.sec.gov/dei/2022": 5, "total": 26 }, "keyCustom": 57, "keyStandard": 239, "memberCustom": 27, "memberStandard": 33, "nsprefix": "irwd", "nsuri": "http://www.ironwoodpharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Net Income Per Share", "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Collaboration, License, and Other Agreements", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements", "shortName": "Collaboration, License, and Other Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Leases", "role": "http://www.ironwoodpharma.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Notes Payable", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Employee Stock Benefit Plans", "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans", "shortName": "Employee Stock Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock Repurchase Plan", "role": "http://www.ironwoodpharma.com/role/DisclosureStockRepurchasePlan", "shortName": "Stock Repurchase Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Income Taxes", "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Subsequent Events", "role": "http://www.ironwoodpharma.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Collaboration, License, and Other Agreements (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "shortName": "Collaboration, License, and Other Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Leases (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Notes Payable (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Employee Stock Benefit Plans (Tables)", "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "shortName": "Employee Stock Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ahMU6-dpSUO3r8-UI7l9zA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ahMU6-dpSUO3r8-UI7l9zA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_2CQJ1G51GUu0Kt5kn8oyRw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_2CQJ1G51GUu0Kt5kn8oyRw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - ASU 2020-06 - Tabular Disclosure (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "shortName": "Summary of Significant Accounting Policies - ASU 2020-06 - Tabular Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_o3TpB4VnTUuCLDYJRA1ZlQ", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ahMU6-dpSUO3r8-UI7l9zA", "decimals": "-5", "first": true, "lang": null, "name": "irwd:InterestExpenseNoncashExpectedIncreaseDecreaseInCurrentFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - ASU 2020-06 - Additional Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - ASU 2020-06 - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ahMU6-dpSUO3r8-UI7l9zA", "decimals": "-5", "first": true, "lang": null, "name": "irwd:InterestExpenseNoncashExpectedIncreaseDecreaseInCurrentFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Net Income Per Share - Computation (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "shortName": "Net Income Per Share - Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZvzAjHLLukGWwYtVgEddNQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Net Income Per Share - Potentially Dilutive Securities (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails", "shortName": "Net Income Per Share - Potentially Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZvzAjHLLukGWwYtVgEddNQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Collaboration, License, and Other Agreements - Summary (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "shortName": "Collaboration, License, and Other Agreements - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementOtherAgreementsMember__BJ2J-n2hUC51B3E2fvpAg", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Collaboration, License, and Other Agreements - Accounts Receivable (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "shortName": "Collaboration, License, and Other Agreements - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Collaboration, License, and Other Agreements - North America - General Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "shortName": "Collaboration, License, and Other Agreements - North America - General Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_0VVg68yYoEqgH0A4RKAHYA", "decimals": "-5", "lang": null, "name": "irwd:LicenseFeesAndMilestonePaymentReceivedCumulative", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Collaboration, License, and Other Agreements - North America - Collaborative Arrangements Revenue (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "shortName": "Collaboration, License, and Other Agreements - North America - Collaborative Arrangements Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementsLinzessMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_QgILbZ4c10OlSminHP6e3Q", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Collaboration, License, and Other Agreements - North America - Commercial Efforts (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "shortName": "Collaboration, License, and Other Agreements - North America - Commercial Efforts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementsLinzessMember_srt_StatementGeographicalAxis_country_US_WB44tKtu4kyhnfZkq_CUOA", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40406 - Disclosure - Collaboration, License, and Other Agreements - North America - Royalty Revenue (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "shortName": "Collaboration, License, and Other Agreements - North America - Royalty Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_srt_StatementGeographicalAxis_irwd_CanadaAndMexicoMember_YqbozcDxWEimXrqbBXM2vA", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Income and Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_CekR5Ne6X0KKPcEoiqq7cw", "decimals": "-3", "lang": null, "name": "irwd:RestructuringExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40407 - Disclosure - Collaboration, License, and Other Agreements - European and Other Territories (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "shortName": "Collaboration, License, and Other Agreements - European and Other Territories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_10_31_2015_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_3qtYTKXvnkuiPWaSkMoACg", "decimals": "-5", "lang": null, "name": "irwd:RemainingMilestonePaymentToBeReceivedByCompanyUponAmendmentToLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40408 - Disclosure - Collaboration, License, and Other Agreements - Japan (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "shortName": "Collaboration, License, and Other Agreements - Japan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AstellasPharmaInc2009LicenseAgreementAmended2019Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_NzVltfPEGESBMjH3hKtNEw", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40409 - Disclosure - Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "shortName": "Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AstraZenecaMember_VQqgcCszd0esdAWGklzQWw", "decimals": "-5", "lang": null, "name": "irwd:MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40410 - Disclosure - Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "shortName": "Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_irwd_AlnylamMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_g0-Wn8AmRkioDn4ZPBe2mg", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2021_Citkn3CnzUu4okweZylPXw", "decimals": "INF", "first": true, "lang": null, "name": "irwd:ThresholdPercentageOfCollateralizedValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Fair Value of Financial Instruments - General Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails", "shortName": "Fair Value of Financial Instruments - General Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2021_Citkn3CnzUu4okweZylPXw", "decimals": "INF", "first": true, "lang": null, "name": "irwd:ThresholdPercentageOfCollateralizedValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sTlYwha70UamIDkxqb8LHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Fair Value of Financial Instruments - Measured on Recurring Basis (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "shortName": "Fair Value of Financial Instruments - Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sTlYwha70UamIDkxqb8LHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "irwd:FairValueTransferBetweenMeasurementLevels", "irwd:FairValueTransferBetweenMeasurementLevels", "irwd:FairValueTransferBetweenMeasurementLevels", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "irwd:FairValueTransferBetweenMeasurementLevels", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Fair Value of Financial Instruments - Transfers Between Fair Value Measurement Levels (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTransfersBetweenFairValueMeasurementLevelsDetails", "shortName": "Fair Value of Financial Instruments - Transfers Between Fair Value Measurement Levels (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "irwd:FairValueTransferBetweenMeasurementLevels", "irwd:FairValueTransferBetweenMeasurementLevels", "irwd:FairValueTransferBetweenMeasurementLevels", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "irwd:FairValueTransferBetweenMeasurementLevels", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7LXRCGwCCUe0rLxLp5talA", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Fair Value of Financial Instruments - Assumptions - Convertible Note Hedges (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "shortName": "Fair Value of Financial Instruments - Assumptions - Convertible Note Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7LXRCGwCCUe0rLxLp5talA", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7LXRCGwCCUe0rLxLp5talA", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40505 - Disclosure - Fair Value of Financial Instruments - Assumptions - Note Hedge Warrants (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails", "shortName": "Fair Value of Financial Instruments - Assumptions - Note Hedge Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7LXRCGwCCUe0rLxLp5talA", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40506 - Disclosure - Fair Value of Financial Instruments - Change in Level 3 - Convertible Note Hedges (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3ConvertibleNoteHedgesDetails", "shortName": "Fair Value of Financial Instruments - Change in Level 3 - Convertible Note Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7xZ9VqS5kaiP_CLjBa0OQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7xZ9VqS5kaiP_CLjBa0OQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40507 - Disclosure - Fair Value of Financial Instruments - Change in Level 3 - Note Hedge Warrants (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3NoteHedgeWarrantsDetails", "shortName": "Fair Value of Financial Instruments - Change in Level 3 - Note Hedge Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes2.25PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_wrTjDpTKWUeivHWPQOMyag", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40508 - Disclosure - Fair Value of Financial Instruments - Notes Payable (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "shortName": "Fair Value of Financial Instruments - Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes2.25PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gQJ8wmKjo0au0qpa1uML_g", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_UT7BOT0UIEG-0gL6joFPmQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OptionIndexedToIssuersEquityShares", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZvzAjHLLukGWwYtVgEddNQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40509 - Disclosure - Fair Value of Financial Instruments - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "shortName": "Fair Value of Financial Instruments - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses and Other Current Liabilities - Tabular Disclosure (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Tabular Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-5", "lang": null, "name": "irwd:OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Leases - Collateral (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails", "shortName": "Leases - Collateral (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RestrictedCash", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_Yb5-PCeU4U6nSu7j3q27hw", "decimals": "-5", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Leases - Lease Cost - Tabular Disclosure (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails", "shortName": "Leases - Lease Cost - Tabular Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40705 - Disclosure - Leases - Operating Lease Obligations (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "shortName": "Leases - Operating Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unitRef": "Unit_Standard_pure_aeUeiU-5s0yduEqX4cHtXg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40706 - Disclosure - Leases - Summer Street Lease (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "shortName": "Leases - Summer Street Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_6_30_2019_srt_CounterpartyNameAxis_irwd_SummerStreetLeaseMember_Vp3__sCzIEeNIgHdx2KThA", "decimals": "-3", "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_r2-Xl3oLw0y4apaJZjWRnA", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_aZ8VEsU1e0OX9tOJrgh2BQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForHedgeInvestingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Notes Payable - General Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails", "shortName": "Notes Payable - General Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_aZ8VEsU1e0OX9tOJrgh2BQ", "decimals": "-5", "lang": null, "name": "irwd:ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Notes Payable - Convertible Senior Notes - Balances (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "shortName": "Notes Payable - Convertible Senior Notes - Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_6_1_2015_To_6_30_2015_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes2.25PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_b77YyB6dO0iQw-tSUc_DiA", "decimals": "-5", "first": true, "lang": null, "name": "irwd:DebtInstrumentDebtIssuanceCostsIncurred", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Notes Payable - Convertible Senior Notes - Additional Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "shortName": "Notes Payable - Convertible Senior Notes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Notes Payable - Convertible Senior Notes - Interest Expense (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails", "shortName": "Notes Payable - Convertible Senior Notes - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - Notes Payable - Convertible Senior Notes - Future Minimum Payments - Tabular Disclosure (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails", "shortName": "Notes Payable - Convertible Senior Notes - Future Minimum Payments - Tabular Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40806 - Disclosure - Notes Payable - Convertible Senior Notes - Future Minimum Payments - Additional Information (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsAdditionalInformationDetails", "shortName": "Notes Payable - Convertible Senior Notes - Future Minimum Payments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_aZ8VEsU1e0OX9tOJrgh2BQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForHedgeInvestingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40807 - Disclosure - Notes Payable - Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "shortName": "Notes Payable - Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes0.75PercentDue2024AndConvertibleSeniorNotes1.50PercentDue2026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_CXG4-JauF0S5WFybiBIr2g", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Epv3mE9JaUiUsab0JAWKFA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40808 - Disclosure - Notes Payable - Convertible Senior Notes Due 2022, Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "shortName": "Notes Payable - Convertible Senior Notes Due 2022, Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes2.25PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_X-Lek71A6keg4ky7Goa8sw", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_4_15_2019_f-LXixpUfUiCA0OcpTXP5w", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_2CQJ1G51GUu0Kt5kn8oyRw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40809 - Disclosure - Notes Payable - Convertible Note Hedge and Warrant Transactions (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "shortName": "Notes Payable - Convertible Note Hedge and Warrant Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_4_15_2019_f-LXixpUfUiCA0OcpTXP5w", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_2CQJ1G51GUu0Kt5kn8oyRw", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_1Qu5HOEz80WNFTwAWmgb5g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_3_31_2021_Citkn3CnzUu4okweZylPXw", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_UT7BOT0UIEG-0gL6joFPmQ", "decimals": "-5", "first": true, "lang": null, "name": "irwd:PaymentMadeForInvestingInCappedCalls", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40810 - Disclosure - Notes Payable - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "shortName": "Notes Payable - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_UT7BOT0UIEG-0gL6joFPmQ", "decimals": "-5", "first": true, "lang": null, "name": "irwd:PaymentMadeForInvestingInCappedCalls", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Employee Stock Benefit Plans - Share-based Compensation Expense - Summary (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails", "shortName": "Employee Stock Benefit Plans - Share-based Compensation Expense - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Tc8ceHbuJE2EbFWBmPIXxQ", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Employee Stock Benefit Plans - Share-based Compensation Expense - Net of Tax (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails", "shortName": "Employee Stock Benefit Plans - Share-based Compensation Expense - Net of Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "us-gaap:TreasuryStockTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_5_31_2021_EnehZDclNUGf6fsdu9R0xg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock Repurchase Program (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails", "shortName": "Stock Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:TreasuryStockTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "As_Of_5_31_2021_EnehZDclNUGf6fsdu9R0xg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_FwdpwVqoxEGyhw15GULZlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Income Taxes (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:TreasuryStockTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZvzAjHLLukGWwYtVgEddNQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Subsequent Events (Details)", "role": "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_4_1_2022_To_4_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VqYuWx2fiEug3kzmsbxniA", "decimals": "-5", "lang": null, "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZvzAjHLLukGWwYtVgEddNQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business", "role": "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irwd-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_zpRevI6Sh0CpFj7q-2N3AA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "perShareItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "irwd_AbbviePlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AbbVie Plc [Member]", "label": "AbbVie" } } }, "localname": "AbbviePlcMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables" ], "xbrltype": "domainItemType" }, "irwd_AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Net of Accounts Payable, Current and Noncurrent", "label": "Accounts Receivable, Net of Accounts Payable, Current and Noncurrent", "terseLabel": "Accounts receivable, net of accounts payable" } } }, "localname": "AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "irwd_AccruedExpensesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued expenses and as well as used to reflect the other current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses and Other Liabilities, Current", "totalLabel": "Total accrued expenses and other current liabilities", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "irwd_AccruedResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development costs, that are statutory in nature, which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research and Development Expense Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "irwd_AccruedStockRepurchaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "order": 3.0, "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Stock Repurchase Liability, Current", "label": "Accrued Stock Repurchase Liability, Current", "terseLabel": "Stock repurchase" } } }, "localname": "AccruedStockRepurchaseLiabilityCurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "irwd_ActivePharmaceuticalIngredientMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Active Pharmaceutical Ingredient [Member]", "label": "Sale of active pharmaceutical ingredient" } } }, "localname": "ActivePharmaceuticalIngredientMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "domainItemType" }, "irwd_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Issuance Costs", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Issuance Costs", "terseLabel": "Equity component of issuance costs for convertible senior notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtIssuanceCosts", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "irwd_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Purchase of Capped Calls", "label": "Adjustments to Additional Paid in Capital, Purchase of Capped Calls", "terseLabel": "Purchase of capped calls" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "irwd_AlnylamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alnylam [Member]", "label": "Alnylam" } } }, "localname": "AlnylamMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_AstellasPharmaInc2009LicenseAgreementAmended2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Astellas Pharma Inc, 2009 License Agreement, Amended 2019 [Member]", "label": "Astellas Pharma Inc., 2009 License Agreement, Amended 2019" } } }, "localname": "AstellasPharmaInc2009LicenseAgreementAmended2019Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails" ], "xbrltype": "domainItemType" }, "irwd_AstellasPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Astellas Pharma Inc [Member]", "label": "Astellas Pharma Inc." } } }, "localname": "AstellasPharmaIncMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CalendarQuarterCommencingAfterDecember312019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to calendar quarter commencing after calendar quarter ending December 31, 2019.", "label": "Calendar quarter commencing after December 31, 2019" } } }, "localname": "CalendarQuarterCommencingAfterDecember312019Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "irwd_CanadaAndMexicoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canada and Mexico [Member]", "label": "Canada and Mexico", "terseLabel": "Canada and Mexico" } } }, "localname": "CanadaAndMexicoMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails" ], "xbrltype": "domainItemType" }, "irwd_ClassOfWarrantOrRightExercisableTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Exercisable, Trading Day Period", "label": "Class of Warrant or Right, Exercisable, Trading Day Period", "terseLabel": "Trading day period" } } }, "localname": "ClassOfWarrantOrRightExercisableTradingDayPeriod", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "durationItemType" }, "irwd_CollaborationAndLicenseAgreementsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and License Agreements Disclosure [Abstract]", "label": "Collaboration and License Agreements Disclosure [Abstract]" } } }, "localname": "CollaborationAndLicenseAgreementsDisclosureAbstract", "nsuri": "http://www.ironwoodpharma.com/20220331", "xbrltype": "stringItemType" }, "irwd_CollaborativeArrangementAmountOfConsiderationTotalNonContingent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount of non-contingent arrangement consideration.", "label": "Collaborative Arrangement, Amount of Consideration Total, Non-contingent", "terseLabel": "Amount of non-contingent arrangement consideration" } } }, "localname": "CollaborativeArrangementAmountOfConsiderationTotalNonContingent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementCoPromotionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Co-promotion Agreement [Member]", "label": "Collaborative arrangement, co-promotion agreements" } } }, "localname": "CollaborativeArrangementCoPromotionAgreementMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementCoPromotionAndOtherAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Co-promotion and Other Agreements [Member]", "label": "Collaborative arrangement, co-promotion and other agreements" } } }, "localname": "CollaborativeArrangementCoPromotionAndOtherAgreementsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementCollaborationAndLicenseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration and License Agreements [Member]", "label": "Collaborative arrangement, collaboration and license agreements" } } }, "localname": "CollaborativeArrangementCollaborationAndLicenseAgreementsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementContingentPaymentPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Contingent Payment, Payable", "label": "Collaborative Arrangement, Contingent Payment, Payable", "terseLabel": "Collaborative arrangement, contingent payment, payable" } } }, "localname": "CollaborativeArrangementContingentPaymentPayable", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementMilestones.PotentialCommercialMilestonePaymentsTermOfAgreementPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones. Potential Commercial Milestone Payments, Term of Agreement, Payable", "label": "Collaborative Arrangement, Milestones. Potential Commercial Milestone Payments, Term of Agreement, Payable", "terseLabel": "Collaborative arrangement, milestones. potential commercial milestone payments, term of agreement, payable" } } }, "localname": "CollaborativeArrangementMilestones.PotentialCommercialMilestonePaymentsTermOfAgreementPayable", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementNonContingentConsiderationNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Non-contingent Consideration Number of Installments", "label": "Collaborative Arrangement, Non-contingent Consideration Number of Installments", "terseLabel": "Non-contingent consideration installments" } } }, "localname": "CollaborativeArrangementNonContingentConsiderationNumberOfInstallments", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "integerItemType" }, "irwd_CollaborativeArrangementNoncontingentInstallmentPaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Noncontingent Installment Payments Receivable", "label": "Collaborative Arrangement, Noncontingent Installment Payments Receivable", "terseLabel": "Collaborative arrangement, non-contingent installment payments receivable" } } }, "localname": "CollaborativeArrangementNoncontingentInstallmentPaymentsReceivable", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementNoncontingentReceivableCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Noncontingent Receivable, Current", "label": "Collaborative Arrangement, Noncontingent Receivable, Current", "terseLabel": "Collaborative arrangement, non-contingent receivable, current" } } }, "localname": "CollaborativeArrangementNoncontingentReceivableCurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementNoncontingentReceivableNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Noncontingent Receivable, Noncurrent", "label": "Collaborative Arrangement, Noncontingent Receivable, Noncurrent", "terseLabel": "Collaborative arrangement, non-contingent receivable, non-current" } } }, "localname": "CollaborativeArrangementNoncontingentReceivableNoncurrent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementOptionToAcquireLicenseExercisePricePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Option to Acquire License, Exercise Price, Payable", "label": "Collaborative Arrangement, Option to Acquire License, Exercise Price, Payable", "terseLabel": "Collaborative arrangement, option to acquire license, exercise price, payable" } } }, "localname": "CollaborativeArrangementOptionToAcquireLicenseExercisePricePayable", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementOtherAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Other Agreements [Member]", "label": "Collaborative arrangement, other agreements" } } }, "localname": "CollaborativeArrangementOtherAgreementsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementPercentageOfNetLoss": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net loss from commercialization.", "label": "Collaborative Arrangement Percentage of Net Loss", "terseLabel": "Percentage of net loss from commercialization (as a percent)" } } }, "localname": "CollaborativeArrangementPercentageOfNetLoss", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_CollaborativeArrangementPercentageOfNetProfit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net profit from commercialization.", "label": "Collaborative Arrangement Percentage of Net Profit", "terseLabel": "Percentage of net profit from commercialization (as a percent)" } } }, "localname": "CollaborativeArrangementPercentageOfNetProfit", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_CollaborativeArrangementPercentageOfObligationOfDevelopmentCostsIncurred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Percentage of Obligation of Development Costs Incurred", "label": "Collaborative Arrangement, Percentage of Obligation of Development Costs Incurred", "terseLabel": "Collaborative arrangement, percentage of obligation of development costs incurred" } } }, "localname": "CollaborativeArrangementPercentageOfObligationOfDevelopmentCostsIncurred", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_CollaborativeArrangementThresholdRoyaltyPercentageOnAnnualNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Threshold Royalty Percentage on Annual Net Sales", "label": "Collaborative Arrangement, Threshold Royalty Percentage on Annual Net Sales", "terseLabel": "Percentage of tiered royalties" } } }, "localname": "CollaborativeArrangementThresholdRoyaltyPercentageOnAnnualNetSales", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "percentItemType" }, "irwd_CollaborativeArrangementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Upfront Payment", "label": "Collaborative Arrangement, Upfront Payment", "terseLabel": "Collaborative arrangement, upfront payment" } } }, "localname": "CollaborativeArrangementUpfrontPayment", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CollaborativeArrangementsAndActivePharmaceuticalIngredientMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements and Active Pharmaceutical Ingredient [Member]", "label": "Collaborative arrangements and active pharmaceutical ingredient" } } }, "localname": "CollaborativeArrangementsAndActivePharmaceuticalIngredientMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementsLinzessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements, LINZESS [Member]", "label": "Collaborative arrangements, LINZESS" } } }, "localname": "CollaborativeArrangementsLinzessMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails" ], "xbrltype": "domainItemType" }, "irwd_CollaborativeArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements [Member]", "label": "Collaborative arrangements revenue" } } }, "localname": "CollaborativeArrangementsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "domainItemType" }, "irwd_ContingentSalesRelatedMilestoneReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent sales-related milestone receivable.", "label": "Contingent Sales-related Milestone Receivable", "terseLabel": "Sales-related milestone if certain conditions are met" } } }, "localname": "ContingentSalesRelatedMilestoneReceivable", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_ConvertibleNoteHedgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to convertible note hedges.", "label": "Convertible Note Hedge" } } }, "localname": "ConvertibleNoteHedgeMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "irwd_ConvertibleSeniorNotes0.75PercentDue2024AndConvertibleSeniorNotes1.50PercentDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026", "label": "0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026" } } }, "localname": "ConvertibleSeniorNotes0.75PercentDue2024AndConvertibleSeniorNotes1.50PercentDue2026Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "irwd_ConvertibleSeniorNotes0.75PercentDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.75% Convertible Senior Notes due 2024", "label": "0.75% Convertible Senior Notes due 2024" } } }, "localname": "ConvertibleSeniorNotes0.75PercentDue2024Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "irwd_ConvertibleSeniorNotes1.50PercentDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.50% Convertible Senior Notes due 2026", "label": "1.50% Convertible Senior Notes due 2026" } } }, "localname": "ConvertibleSeniorNotes1.50PercentDue2026Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "irwd_ConvertibleSeniorNotes2.25PercentDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.25% Convertible Senior Notes due 2022", "label": "2.25% Convertible Senior Notes due 2022" } } }, "localname": "ConvertibleSeniorNotes2.25PercentDue2022Member", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "irwd_CostSharingArrangementReductionToResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the reduction to research and development expense for the amount received from the collaboration partner under cost sharing provisions.", "label": "Cost Sharing Arrangement Reduction to Research and Development Expense", "terseLabel": "Cost sharing amount, reduction to research and development" } } }, "localname": "CostSharingArrangementReductionToResearchAndDevelopmentExpense", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_CourPharmaceuticalsDevelopmentCompanyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COUR Pharmaceuticals Development Company, Inc. [Member]", "label": "COUR Pharmaceuticals Development Company, Inc.", "terseLabel": "COUR Pharmaceuticals Development Company, Inc." } } }, "localname": "CourPharmaceuticalsDevelopmentCompanyIncMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "irwd_DebtDefaultDebtInstrumentPayableDueToEventOfDefaultAsPercentageOfAggregatePrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of aggregate principal amount payable in case of event of default.", "label": "Debt Default Debt Instrument Payable Due To Event Of Default As Percentage Of Aggregate Principal Amount", "terseLabel": "Percentage of aggregate principal amount payable, in case of event of default" } } }, "localname": "DebtDefaultDebtInstrumentPayableDueToEventOfDefaultAsPercentageOfAggregatePrincipalAmount", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of principal amount of debt arrived at as the repurchase price under the debt conversion arrangement.", "label": "Debt Instrument Conditional Conversion, Repurchase Price Principal Percentage", "terseLabel": "Repurchase price" } } }, "localname": "DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "percentItemType" }, "irwd_DebtInstrumentConversionObligationNumberOfBusinessDaysAfterConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of business days immediately after any five consecutive trading day period during the debt instrument measurement period.", "label": "Debt Instrument Conversion Obligation Number Of Business Days After Consecutive Trading Day Period", "terseLabel": "Number of business days immediately after any five consecutive trading day period during the measurement period" } } }, "localname": "DebtInstrumentConversionObligationNumberOfBusinessDaysAfterConsecutiveTradingDayPeriod", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "integerItemType" }, "irwd_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.", "label": "Debt Instrument Conversion Obligation Period Of Consecutive Trading Days", "terseLabel": "Number of consecutive trading days before five business days during the measurement period" } } }, "localname": "DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "integerItemType" }, "irwd_DebtInstrumentConversionPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of conversion premium above the last reported sale price of common stock.", "label": "Debt Instrument, Conversion Premium", "terseLabel": "Conversion premium percentage on sale price of common stock" } } }, "localname": "DebtInstrumentConversionPremium", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "percentItemType" }, "irwd_DebtInstrumentConvertibleDebtIssuanceCostAllocatedToEquityComponents": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails": { "order": 1.0, "parentTag": "irwd_DebtInstrumentDebtIssuanceCostsIncurred", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of debt issuance costs allocated to the equity component of the convertible debt.", "label": "Debt Instrument Convertible Debt Issuance Cost Allocated To Equity Components", "terseLabel": "Debt issuance costs allocated to equity components" } } }, "localname": "DebtInstrumentConvertibleDebtIssuanceCostAllocatedToEquityComponents", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "monetaryItemType" }, "irwd_DebtInstrumentConvertibleDebtIssuanceCostAllocatedToLiabilityComponents": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails": { "order": 2.0, "parentTag": "irwd_DebtInstrumentDebtIssuanceCostsIncurred", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of debt issuance costs allocated to the liability component of the convertible debt.", "label": "Debt Instrument Convertible Debt Issuance Cost Allocated To Liability Components", "terseLabel": "Debt issuance costs allocated to liability components" } } }, "localname": "DebtInstrumentConvertibleDebtIssuanceCostAllocatedToLiabilityComponents", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "monetaryItemType" }, "irwd_DebtInstrumentDebtIssuanceCostsIncurred": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt issuance costs incurred.", "label": "Debt Instrument, Debt Issuance Costs Incurred", "terseLabel": "Debt issuance costs incurred", "totalLabel": "Debt issuance costs incurred" } } }, "localname": "DebtInstrumentDebtIssuanceCostsIncurred", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "monetaryItemType" }, "irwd_DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Default Payment, Percentage of Principal Amount of Notes Outstanding", "label": "Debt Instrument Default Payment, Percentage of Principal Amount of Notes Outstanding", "terseLabel": "Percentage of aggregate principal amount of notes outstanding and payable in case of event of default under the agreement" } } }, "localname": "DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "percentItemType" }, "irwd_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument principal amount denomination for conversion into common stock.", "label": "Debt Instrument, Principal Amount Denomination for Conversion into Common Stock", "terseLabel": "Principal amount used for debt instrument conversion ratio" } } }, "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the price at which the debt may be repurchased, as a percentage of the principal amount if the entity undergoes a change of control.", "label": "Debt Instrument Repurchase Price Due To Change In Control As Percentage Of Principal Amount", "terseLabel": "Repurchase price, as percentage of principal amount, if company undergoes change of control" } } }, "localname": "DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_EuropeAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe and Other [Member]", "label": "Europe and Other", "terseLabel": "Europe and Other" } } }, "localname": "EuropeAndOtherMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "irwd_FairValueAdjustmentOfConvertibleNoteHedgingInstrument": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability designated as a hedging instrument.", "label": "Fair Value Adjustment Of Convertible Note Hedging Instrument", "terseLabel": "Change in fair value of convertible note hedges" } } }, "localname": "FairValueAdjustmentOfConvertibleNoteHedgingInstrument", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "irwd_FairValueTransferBetweenMeasurementLevels": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers measured on recurring basis between measurement levels.", "label": "Fair Value Transfer Between Measurement Levels", "verboseLabel": "Fair value transfer between measurement levels" } } }, "localname": "FairValueTransferBetweenMeasurementLevels", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTransfersBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the net change in research and development expenses, which are accrued during the period, but not yet paid.", "label": "Increase (Decrease) in Accrued Research and Development Expense", "terseLabel": "Accrued research and development costs" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpense", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "irwd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease, Right-of-Use Asset", "label": "Increase (Decrease) in Operating Lease, Right-of-Use Asset", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "irwd_InterestExpenseNoncashExpectedIncreaseDecreaseInCurrentFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest Expense, Noncash, Expected Increase (Decrease) in Current Fiscal Year", "label": "Interest Expense, Noncash, Expected Increase (Decrease) in Current Fiscal Year", "terseLabel": "Interest expense, non-cash, expected increase (decrease) in current fiscal year" } } }, "localname": "InterestExpenseNoncashExpectedIncreaseDecreaseInCurrentFiscalYear", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "2027 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "irwd_LicenseFeesAndMilestonePaymentReceivedCumulative": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cumulative amount of license fees and milestone payments received to date.", "label": "License Fees and Milestone Payment Received Cumulative", "terseLabel": "Cumulative license fees and development milestone payments received" } } }, "localname": "LicenseFeesAndMilestonePaymentReceivedCumulative", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_LongTermDebtMaturitiesInterestPayments": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of interest to be paid on long-term debt.", "label": "Long-term Debt, Maturities, Interest Payments", "negatedLabel": "Less: amounts representing interest" } } }, "localname": "LongTermDebtMaturitiesInterestPayments", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "irwd_MaximumPeriodOfSoleRemedyForEventFailures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents maximum period of the sole remedy for event failures in the Indenture.", "label": "Maximum Period Of The Sole Remedy For Event Failures", "terseLabel": "Maximum period of the sole remedy for event failures in the Indenture" } } }, "localname": "MaximumPeriodOfSoleRemedyForEventFailures", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "irwd_MeasurementPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to measurement period.", "label": "Measurement period" } } }, "localname": "MeasurementPeriodMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "irwd_MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount to be received by the company upon completion of milestone.", "label": "Milestone Payment to be Received by Company upon Milestone Achievement", "terseLabel": "Milestone payment to be received by company upon milestone achievement" } } }, "localname": "MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_NoteHedgeWarrantDerivativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Hedge Warrant derivatives.", "label": "Note Hedge Warrant Derivatives" } } }, "localname": "NoteHedgeWarrantDerivativesMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "domainItemType" }, "irwd_NoteHedgeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Hedge Warrants to acquire shares of Class A common stock.", "label": "Note Hedge Warrants" } } }, "localname": "NoteHedgeWarrantsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "domainItemType" }, "irwd_NumberOfMilestonePaymentsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestone payments received.", "label": "Number of Milestone Payments Received", "terseLabel": "Number of milestone payments received" } } }, "localname": "NumberOfMilestonePaymentsReceived", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "irwd_NumberOfRemainingCommercialPeriodPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Remaining Commercial Period Performance Obligations.", "label": "Number of Remaining Commercial Period Performance Obligations", "terseLabel": "Remaining commercial-period performance obligations" } } }, "localname": "NumberOfRemainingCommercialPeriodPerformanceObligations", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "irwd_OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Accrued Liabilities, Current, Uninvoiced Vendor Liabilities", "label": "Other Accrued Liabilities, Current, Uninvoiced Vendor Liabilities", "terseLabel": "Other accrued liabilities, uninvoiced vendor liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_PaymentMadeForInvestingInCappedCalls": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of payment made to counterparties to enter in to capped calls.", "label": "Payment Made for Investing in Capped Calls", "terseLabel": "Payment made to enter into Capped Calls" } } }, "localname": "PaymentMadeForInvestingInCappedCalls", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "irwd_PercentageOfIncreaseInOperatingLeaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual rent escalation in initial lease period and in renewal period.", "label": "Percentage of Increase in Operating Lease Rent", "terseLabel": "Annual rent escalation (as a percent)" } } }, "localname": "PercentageOfIncreaseInOperatingLeaseRent", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "percentItemType" }, "irwd_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units [Member]", "label": "Performance-based Restricted Stock Units" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "irwd_PeriodOverWhichAnnualRoyaltyWillBePaidAsPercentageOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period over which annual royalty will be paid as a percentage on net sales of products containing linaclotide as an active ingredient in the upper-single digits.", "label": "Period Over Which Annual Royalty Will Be Paid as a Percentage On Net Sales", "terseLabel": "Annual royalty" } } }, "localname": "PeriodOverWhichAnnualRoyaltyWillBePaidAsPercentageOnNetSales", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "xbrltype": "durationItemType" }, "irwd_ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Partial Termination of Convertible Note Hedges and Warrants", "label": "Proceeds from Partial Termination of Convertible Note Hedges and Warrants", "terseLabel": "Proceeds from partial termination of convertible note hedges and note hedge warrants" } } }, "localname": "ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "irwd_RemainingMilestonePaymentToBeReceivedByCompanyUponAmendmentToLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be received by the company upon amendment to the license agreement.", "label": "Remaining Milestone Payment to be Received by Company upon Amendment to License Agreement", "verboseLabel": "Remaining milestone payment due upon the amendment to the license agreement" } } }, "localname": "RemainingMilestonePaymentToBeReceivedByCompanyUponAmendmentToLicenseAgreement", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "xbrltype": "monetaryItemType" }, "irwd_RepurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The information pertaining to repurchase agreement", "label": "Repurchase agreements" } } }, "localname": "RepurchaseAgreementMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "irwd_RestrictedCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash Equivalents, Fair Value Disclosure.", "label": "Restricted Cash Equivalents, Fair Value Disclosure", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashEquivalentsFairValueDisclosure", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "irwd_RestructuringExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring Expense (Benefit)", "label": "Restructuring Expense (Benefit)", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringExpenseBenefit", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "irwd_ScheduleOfInterestOnConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense and the effective interest rate on the convertible debt.", "label": "Schedule of Interest on Convertible Debt [Table Text Block]", "verboseLabel": "Schedule of interest expense related to Convertible Notes" } } }, "localname": "ScheduleOfInterestOnConvertibleDebtTableTextBlock", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "irwd_SignificantFinancingComponentTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Significant Financing Component, Transaction Price", "label": "Significant Financing Component, Transaction Price", "terseLabel": "Collaborative arrangement, significant financing component, transaction price" } } }, "localname": "SignificantFinancingComponentTransactionPrice", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "xbrltype": "monetaryItemType" }, "irwd_StockRepurchasedAndRetiredDuringPeriodWeightedAveragePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchased and Retired During Period, Weighted-average Price", "label": "Stock Repurchased and Retired During Period, Weighted-average Price", "terseLabel": "Common stock repurchased and retired, weighted-average price (in dollars per share)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodWeightedAveragePrice", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "irwd_SummerStreetLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to summer street lease.", "label": "Summer Street Lease" } } }, "localname": "SummerStreetLeaseMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "domainItemType" }, "irwd_ThresholdPercentageOfCollateralizedValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of threshold collateralized value.", "label": "Threshold Percentage of Collateralized Value", "verboseLabel": "Threshold percentage of collateralized value (as a percent)" } } }, "localname": "ThresholdPercentageOfCollateralizedValue", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "irwd_TimeBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time-based Restricted Stock Units [Member]", "label": "Time-based Restricted Stock Units" } } }, "localname": "TimeBasedRestrictedStockUnitsMember", "nsuri": "http://www.ironwoodpharma.com/20220331", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r42", "r86", "r87", "r210", "r252" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r93", "r102", "r175", "r319", "r320", "r321", "r336", "r337", "r380", "r385", "r386", "r456" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r93", "r102", "r108", "r175", "r319", "r320", "r321", "r336", "r337", "r380", "r383", "r385", "r386", "r456" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r93", "r102", "r108", "r175", "r319", "r320", "r321", "r336", "r337", "r380", "r383", "r385", "r386", "r456" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r93", "r102", "r108", "r175", "r319", "r320", "r321", "r336", "r337", "r380", "r383", "r385", "r386", "r456" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r188", "r189", "r190", "r191", "r209", "r251", "r280", "r282", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r517", "r520", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r188", "r189", "r190", "r191", "r209", "r251", "r280", "r282", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r517", "r520", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r159", "r189", "r190", "r263", "r264", "r478", "r516", "r518" ], "lang": { "en-us": { "role": { "label": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r159", "r189", "r190", "r263", "r264", "r478", "r516", "r518" ], "lang": { "en-us": { "role": { "label": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r183", "r188", "r189", "r190", "r191", "r209", "r251", "r271", "r280", "r282", "r309", "r310", "r311", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r517", "r520", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r183", "r188", "r189", "r190", "r191", "r209", "r251", "r271", "r280", "r282", "r309", "r310", "r311", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r517", "r520", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r41", "r42", "r86", "r87", "r210", "r252" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r103", "r108", "r187", "r281" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r160", "r161", "r263", "r265", "r519", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r160", "r161", "r263", "r265", "r519", "r541", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r103", "r108", "r187", "r281", "r464" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202104Member": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update 2021-04 [Member]", "terseLabel": "Accounting Standards Update 2021-04" } } }, "localname": "AccountingStandardsUpdate202104Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r461" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r490", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r501", "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r163", "r164" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetNoncurrent": { "auth_ref": [ "r163", "r489", "r501" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Accounts receivable, net of current portion" } } }, "localname": "AccountsReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r14", "r486", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalFairValueElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Fair Value Elements [Abstract]", "terseLabel": "Fair value transfers" } } }, "localname": "AdditionalFairValueElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTransfersBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r18" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r319", "r320", "r321", "r385" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r95", "r96", "r97", "r98", "r108", "r166", "r167", "r172", "r173", "r174", "r175", "r176", "r177", "r319", "r320", "r321", "r334", "r335", "r336", "r337", "r348", "r349", "r350", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r418", "r419", "r433", "r434", "r435", "r436", "r453", "r454", "r455", "r456", "r457", "r458", "r479", "r480", "r481", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Equity component of convertible senior notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r283", "r323", "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation expense related to share-based awards and employee stock purchase plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r314" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total share-based compensation expense included in costs and expenses, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r60", "r73", "r229", "r422" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r56", "r73", "r229", "r424" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r73", "r229", "r242", "r243", "r424" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Rentable area leased (in square feet)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r82", "r149", "r152", "r157", "r168", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r356", "r361", "r400", "r459", "r461", "r484", "r502" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r24", "r82", "r168", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r356", "r361", "r400", "r459", "r461" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r389" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CallOptionMember": { "auth_ref": [ "r535", "r536", "r537", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.", "label": "Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes" } } }, "localname": "CallOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r10", "r75" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r75", "r78" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r410" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r94", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r334", "r348", "r349", "r370", "r376", "r377", "r388", "r401", "r403", "r404", "r405", "r408", "r409", "r418", "r431", "r433", "r434", "r435", "r453", "r454", "r479", "r480", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "verboseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r102", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r334", "r348", "r349", "r350", "r370", "r376", "r377", "r378", "r382", "r388", "r401", "r403", "r404", "r405", "r408", "r409", "r418", "r431", "r433", "r434", "r435", "r453", "r454", "r479", "r480", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "verboseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList": { "auth_ref": [ "r2", "r3", "r178", "r179", "r337", "r379", "r384", "r420", "r427", "r428", "r429", "r430", "r432", "r436", "r437", "r438", "r455", "r523", "r533" ], "lang": { "en-us": { "role": { "documentation": "Indicates transition method applied for adoption of amendment to accounting standards.", "label": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_ClassOfStockDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Stock Repurchase Program" } } }, "localname": "ClassOfStockDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r261", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants strike price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Shares into which warrants may be converted (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r351", "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration, License, and Other Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "verboseLabel": "Collaboration, License, Promotion and Other Commercial Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r491", "r509" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91", "r385" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common stock" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r461" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 155,115,155 shares issued and outstanding at March 31, 2022 and 500,000,000 shares authorized and 162,036,461 shares issued and outstanding at December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r46", "r47", "r54", "r494", "r512" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r79", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Current portion of convertible senior notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible senior notes, net of current portion", "verboseLabel": "Long-term portion of convertible senior notes" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r13", "r485", "r500", "r534" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Senior Notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issuable upon conversion of debt (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r80", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r223", "r230", "r231", "r233", "r246" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r81", "r88", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r240", "r241", "r242", "r243", "r425", "r485", "r487", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r235", "r487", "r500" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total future minimum payments under the convertible senior notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Total equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r208", "r237" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)", "verboseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r31", "r208", "r254", "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "verboseLabel": "Conversion rate, number of shares to be issued per" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Minimum percentage of stock price" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Number of trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r206", "r240", "r241", "r423", "r425", "r426" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount of notes issued", "verboseLabel": "Aggregate principal amount of notes issued" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Fees and expenses" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r30", "r238", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate on liability components" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r30", "r207" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Stated interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33", "r81", "r88", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r240", "r241", "r242", "r243", "r425" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt redemption/repurchase price" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt redeemed/repurchased" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r33", "r81", "r88", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r232", "r240", "r241", "r242", "r243", "r254", "r256", "r257", "r258", "r422", "r423", "r425", "r426", "r499" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r219", "r422", "r426" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 }, "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less: unamortized debt discount", "negatedTerseLabel": "Less: unamortized debt discount", "terseLabel": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]", "terseLabel": "Notes Payable" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r327", "r328" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r73", "r83", "r333", "r340", "r341", "r342" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r180" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetMeasurementInput": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative asset.", "label": "Derivative Asset, Measurement Input", "terseLabel": "Derivative asset, measurement input" } } }, "localname": "DerivativeAssetMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssetValuationTechniqueExtensibleList": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Indicates valuation technique for measuring derivative asset.", "label": "Derivative Asset, Valuation Technique [Extensible Enumeration]", "terseLabel": "Derivative asset, valuation technique" } } }, "localname": "DerivativeAssetValuationTechniqueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r38", "r39", "r42", "r399" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Convertible note hedges" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCapPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.", "label": "Derivative, Cap Price", "terseLabel": "Cap price" } } }, "localname": "DerivativeCapPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r42", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r38", "r39", "r42", "r399" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Note hedge warrants" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input", "terseLabel": "Derivative liability, measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Indicates valuation technique for measuring derivative liability.", "label": "Derivative Liability, Valuation Technique [Extensible Enumeration]", "terseLabel": "Derivative liability, valuation technique" } } }, "localname": "DerivativeLiabilityValuationTechniqueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Add back interest expense, net of tax benefit, on assumed conversion of convertible notes" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of revenue attributable to transactions from collaboration and license arrangements" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r286", "r287", "r315", "r316", "r317", "r325" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Employee Stock Benefit Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Disclosure Text Block" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes", "http://www.ironwoodpharma.com/role/DisclosureLeases", "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShare", "http://www.ironwoodpharma.com/role/DisclosureNotesPayable", "http://www.ironwoodpharma.com/role/DisclosureStockRepurchasePlan", "http://www.ironwoodpharma.com/role/DisclosureSubsequentEvents", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r55", "r100", "r101", "r102", "r103", "r104", "r109", "r112", "r124", "r125", "r126", "r130", "r131", "r386", "r387", "r495", "r513" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r55", "r100", "r101", "r102", "r103", "r104", "r112", "r124", "r125", "r126", "r130", "r131", "r386", "r387", "r495", "r513" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Potentially dilutive securities" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "order": 1.0, "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]", "terseLabel": "Employee Stock Benefit Plans" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r314" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseNetOfTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r48", "r49", "r50", "r90", "r91", "r92", "r96", "r105", "r107", "r135", "r175", "r253", "r259", "r319", "r320", "r321", "r336", "r337", "r385", "r411", "r412", "r413", "r414", "r415", "r416", "r458", "r523", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Adjustment Disclosure [Abstract]", "terseLabel": "Fair value disclosures" } } }, "localname": "FairValueAdjustmentDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r73", "r247" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of note hedge warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r389", "r390", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Change in Level 3 Assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3ConvertibleNoteHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r394", "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of the change in Level 3 assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r240", "r241", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r390", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r389", "r390", "r392", "r393", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r221", "r272", "r273", "r278", "r279", "r390", "r466" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r240", "r241", "r272", "r273", "r278", "r279", "r390", "r467" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r221", "r240", "r241", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r390", "r468" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Inputs, Quantitative Information [Abstract]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Change in Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3NoteHedgeWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r394", "r397" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r394", "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of the change in Level 3 liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value, recorded as a component of gain on derivatives" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3ConvertibleNoteHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3ConvertibleNoteHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedLabel": "Change in fair value, recorded as a component of gain on derivatives" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3NoteHedgeWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value", "negatedPeriodEndLabel": "Balance at end of period", "negatedPeriodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3NoteHedgeWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r221", "r240", "r241", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).", "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income" } } }, "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3ConvertibleNoteHedgesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income" } } }, "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInLevel3NoteHedgeWarrantsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r366" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain on derivatives" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r73", "r244", "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingAssetsCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the asset arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.", "label": "Hedging Assets, Current", "terseLabel": "Convertible note hedges" } } }, "localname": "HedgingAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingAssetsNoncurrent": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the asset arising from a financial instrument or a contract used to hedge price changes in underlying assets, and which are expected to be converted into cash or otherwise disposed of after a year or beyond the normal operating cycle, if longer.", "label": "Hedging Assets, Noncurrent", "verboseLabel": "Long-term asset" } } }, "localname": "HedgingAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.", "label": "Hedging Liabilities, Current", "terseLabel": "Note hedge warrants" } } }, "localname": "HedgingLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability arising from a financial instrument or contract used to mitigate a specified risk (hedge), expected to be settled after one year or beyond the normal operating cycle, if longer.", "label": "Hedging Liabilities, Noncurrent", "verboseLabel": "Long-term liability" } } }, "localname": "HedgingLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r52", "r149", "r151", "r153", "r156", "r158", "r482", "r492", "r497", "r514" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r182", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r84", "r330", "r331", "r332", "r338", "r343", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r85", "r106", "r107", "r148", "r329", "r339", "r344", "r515" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r72", "r446" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity (Deficit)" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r120", "r121", "r126" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Effect of dilutive securities, convertible notes" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r113", "r114", "r115", "r126", "r284" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive securities, share-based compensation" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r51", "r147", "r421", "r424", "r496" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r60", "r227", "r239", "r242", "r243" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Non-cash interest expense", "totalLabel": "Total interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt [Abstract]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r61", "r228", "r242", "r243" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "order": 2.0, "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r58", "r60" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r449", "r451" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of components of lease cost and supplemental cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend the term of the lease" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r450" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r82", "r168", "r400", "r461", "r488", "r507" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r29", "r82", "r168", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r357", "r361", "r362", "r400", "r459", "r460", "r461" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r389" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r220", "r236", "r240", "r241", "r487", "r504" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "totalLabel": "Net carrying amount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Unclassified [Abstract]", "terseLabel": "Liability component:" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Long-term debt, current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities [Abstract]", "terseLabel": "Notes Payable" } } }, "localname": "LongTermDebtCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Estimated fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r88", "r192", "r225" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r88", "r192", "r225" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r88", "r192", "r225" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r88", "r192", "r225" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r88" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTerm": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Long-term Debt, Term", "terseLabel": "Debt instrument term" } } }, "localname": "LongTermDebtTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "xbrltype": "durationItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r33", "r193" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsNotesPayableDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturities of Long-term Debt [Abstract]", "terseLabel": "Future minimum payments of Convertible senior notes" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsConvertibleNoteHedgesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsAssumptionsNoteHedgeWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r136", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r74" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r43", "r45", "r50", "r53", "r74", "r82", "r95", "r100", "r101", "r102", "r103", "r106", "r107", "r122", "r149", "r151", "r153", "r156", "r158", "r168", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r387", "r400", "r493", "r511" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r100", "r101", "r102", "r103", "r109", "r110", "r123", "r126", "r149", "r151", "r153", "r156", "r158" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) available to common stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r111", "r116", "r117", "r118", "r119", "r123", "r126" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income (loss) available to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r93", "r95", "r96", "r97", "r98", "r99", "r102", "r108", "r130", "r166", "r167", "r172", "r173", "r174", "r175", "r176", "r177", "r319", "r320", "r321", "r334", "r335", "r336", "r337", "r348", "r349", "r350", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r418", "r419", "r433", "r434", "r435", "r436", "r453", "r454", "r455", "r456", "r457", "r458", "r479", "r480", "r481", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r151", "r153", "r156", "r158" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]" } } }, "localname": "OperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r444", "r451" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]", "terseLabel": "Operating lease obligations" } } }, "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Future minimum lease payments" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r440" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liability", "totalLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r440" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion of operating lease liabilities", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r440" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligations, net of current portion", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r441", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r439" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r448", "r451" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate of operating leases (as a percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r447", "r451" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r249", "r371", "r372", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityTable": { "auth_ref": [ "r249", "r371", "r372", "r375" ], "lang": { "en-us": { "role": { "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options.", "label": "Option Indexed to Issuer's Equity, Equity [Table]" } } }, "localname": "OptionIndexedToIssuersEquityEquityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Option Indexed to Issuer's Equity [Line Items]", "terseLabel": "Capped Calls" } } }, "localname": "OptionIndexedToIssuersEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityShares": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract.", "label": "Option Indexed to Issuer's Equity, Shares", "terseLabel": "Number of shares covered by capped calls (in shares)" } } }, "localname": "OptionIndexedToIssuersEquityShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r248", "r373" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Strike price (in dollars per share)" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "order": 4.0, "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForHedgeInvestingActivities": { "auth_ref": [ "r63", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for Hedge, Investing Activities", "terseLabel": "Payments for convertible note hedges" } } }, "localname": "PaymentsForHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r66" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDerivativeIssuanceCosts": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of a derivative security.", "label": "Payments of Derivative Issuance Costs", "terseLabel": "Net derivative issuance cost" } } }, "localname": "PaymentsOfDerivativeIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleNoteHedgeAndWarrantTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r62" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policy Text Block [Abstract]", "terseLabel": "Policy Text Blocks" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r250" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r250" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "verboseLabel": "Net proceed received" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "verboseLabel": "Equity investment in the entity's capital stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r64", "r318" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r43", "r45", "r50", "r68", "r82", "r95", "r106", "r107", "r149", "r151", "r153", "r156", "r158", "r168", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r355", "r359", "r360", "r363", "r364", "r387", "r400", "r497" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r181", "r461", "r498", "r508" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r326", "r477", "r555" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r10", "r78", "r483", "r505" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash [Abstract]" } } }, "localname": "RestrictedCashAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r10", "r78" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r11", "r78", "r542" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, net of current portion" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring expenses" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r259", "r461", "r506", "r527", "r532" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r90", "r91", "r92", "r96", "r105", "r107", "r175", "r319", "r320", "r321", "r336", "r337", "r385", "r523", "r525" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r145", "r146", "r150", "r154", "r155", "r159", "r160", "r162", "r262", "r263", "r478" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that have been excluded from computation of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all information related to the key inputs and assumptions (including, at a minimum, but not limited to, and if applicable, quantitative information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses) used in measuring the fair value of assets or liabilities that relate to the transferor's continuing involvement with transferred financial assets, as of the balance sheet date.", "label": "Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]", "terseLabel": "Schedule of assumptions used in fair market valuations" } } }, "localname": "ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of outstanding Convertible Note" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r313", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Share-based compensation expense reflected in the condensed consolidated statements of operations" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of future minimum payments details of debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r99", "r102", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Schedule of ASU 2020-06 cumulative-effect adjustment" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r78", "r483", "r505" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesCollateralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r445", "r451" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r36", "r48", "r49", "r50", "r90", "r91", "r92", "r96", "r105", "r107", "r135", "r175", "r253", "r259", "r319", "r320", "r321", "r336", "r337", "r385", "r411", "r412", "r413", "r414", "r415", "r416", "r458", "r523", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r135", "r478" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r253", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r259", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based awards and employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.", "label": "Stock Repurchase Program Expiration Date", "terseLabel": "Stock repurchase program, expiration date" } } }, "localname": "StockRepurchaseProgramExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails" ], "xbrltype": "dateItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r16", "r17", "r253", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Repurchases of common stock (in shares)", "terseLabel": "Common stock repurchased and retired (in shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails", "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r16", "r17", "r253", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Repurchases of common stock", "terseLabel": "Common stock repurchased and retired" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchaseProgramDetails", "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r82", "r165", "r168", "r400", "r461" ], "calculation": { "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r417", "r463" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r417", "r463" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r417", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r417", "r463" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r462", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Table Text Block [Abstract]", "terseLabel": "Table Text Blocks" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesTables", "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareTables", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "Share Repurchase Plan" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockRepurchasePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r95", "r96", "r97", "r98", "r108", "r166", "r167", "r172", "r173", "r174", "r175", "r176", "r177", "r319", "r320", "r321", "r334", "r335", "r336", "r337", "r348", "r349", "r350", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r418", "r419", "r433", "r434", "r435", "r436", "r453", "r454", "r455", "r456", "r457", "r458", "r479", "r480", "r481", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006AdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAsu202006TabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 }, "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureNotesPayableConvertibleSeniorNotesFutureMinimumPaymentsTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r137", "r138", "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r126" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net income per share - diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding used in computing net income per share - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r126" ], "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net income per share - basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding used in computing net income per share - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Initial debt issuance costs" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNotesPayableGeneralInformationDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/subtopic&trid=2208821" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(2),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL119206272-209984" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL119206272-209984" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(k)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r556": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r557": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r559": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r560": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r561": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3581-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" }